Prospectus, including new financial information, regarding

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Prospectus, including new financial information, regarding Oasmia Pharmaceutical's rights issue is now available

Uppsala, Sweden, 2014-11-17 17:32 CET (GLOBE NEWSWIRE) --  

The Board of Directors of Oasmia Pharmaceutical AB (publ) (“Oasmia”) has prepared a prospectus for the purpose of the rights issue (the “Rights Issue”), which was announced on November 11, 2014.

The prospectus has today been approved by and registered with the Swedish Financial Supervisory Authority (Swe. Finansinspektionen) and is now available on Oasmia's website (www.oasmia.com), Carnegie Investment Bank AB's website (www.carnegie.se) and the Swedish Financial Supervisory Authority's website ( www.fi.se ). The prospectus can also be ordered from Carnegie Investment Bank AB during business hours by telephone +46 (0)8 5886 8660.

The Company publishes in the prospectus liabilities, equity and net debt as of September 30, 2014. The current liabilities amount to 187,435 KSEK, the non-current liabilities amount to 891 KSEK and the equity amounts to 278,028 KSEK. The net debt amounts to 107,544 KSEK. 

Indicative time table for the Rights Issue

November 14, 2014                         Last day of trading in the shares including preferential rights to participate in the Rights Issue

November 17, 2014                         First day of trading in the shares excluding preferential rights to participate in the Rights Issue

November 17, 2014                         Publication of the prospectus

November 18, 2014                         Record date for participation in the Rights Issue, i.e. shareholders who are registered in Oasmia’s share ledger on this day will receive subscription rights for participation in the Rights Issue

November 19 –                                Subscription period
December 5, 2014                                                  

November 19 –                                Trading in subscription rights
December 3, 2014                                                  

November 19 –                                Trading in paid subscribed shares (BTA)
December 15, 2014                                               

December 4, 2014                           The interim report for the period May 1 to October 31, 2014, is made available

December 8, 2014                           Announcement of preliminary outcome of the Rights Issue

December 10, 2014                         Announcement of final outcome of the Rights Issue

December 17, 2014                         First day of trading with the new shares

Financial and legal advisors

Carnegie Investment Bank AB (publ) is financial advisor and Gernandt & Danielsson Advokatbyrå KB is legal advisor to Oasmia.  

About Oasmia
Oasmia develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, compared to current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. Product development is based on in-house research within nanotechnology and proprietary patents. Oasmia’s shares, ISIN SE0000722365, are listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX).

IMPORTANT INFORMATION

Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the constituent information in accordance with the rules and regulations prevailing in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Oasmia Pharmaceutical AB (publ) securities in any jurisdiction, neither from Oasmia Pharmaceutical AB (publ), Carnegie Investment Bank AB (publ) nor anyone else.

Oasmia is required to announce the information in this press release in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published 17.30 am on November 17, 2014.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended. Oasmia does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or the United States or in any jurisdiction in which the distribution of this release would be unlawful.

This document has not been approved by any regulatory authority. This document is an advertisement and not a prospectus and investors should not subscribe for, or purchase, any securities referred to in this document, except on the basis of information provided in the prospectus to be published by Oasmia on its web site due to the rights issue.

Oasmia has not authorized any offer to the public of shares or rights in any Member State of the European Economic Area other than Sweden and any other jurisdiction into which the offering of shares or rights has been passported or in which other exemptions are applicable. With respect to each Member State of the European Economic Area other than Sweden (and any other jurisdiction into which the offering of shares or rights has been passported) and which has implemented the Prospectus Directive (each, a “Relevant Member State”), no action has been undertaken to date to make an offer to the public of shares or rights requiring a publication of a prospectus in any Relevant Member State. As a result, the shares or rights may only be offered in a Relevant Member State:

(a) to legal entities which are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities;

(b) to any legal entity meeting two or more of the following criteria: (1) a balance sheet total pursuant to the balance sheet equivalent to not less than EUR 20 million; (2) net turnover pursuant to the balance sheet equivalent to not less than EUR 40 million; and shareholders’ equity pursuant to the balance sheet equivalent to not less than EUR 2 million; or

(c) in any other circumstances, not requiring Oasmia to publish a prospectus as provided under Article 3(2) of the Prospectus Directive.

For the purposes hereof, the expression an “offer to the public of Shares or Rights” in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares or rights to be offered so as to enable an investor to decide to purchase any securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State and the expression “Prospectus Directive” means Directive 2003/71/EC as amended and includes any relevant implementing measure in each Relevant Member State.

Carnegie is acting for Oasmia and no one else in connection with the rights offering and will not be responsible to anyone other than Oasmia for providing the protections afforded to its clients or for providing advice in relation to the rights offering and/or any other matter referred to in this announcement.

Carnegie accepts no responsibility whatsoever and makes no representation or warranty, express or implied, for the contents of this announcement, including its accuracy, completeness or verification or for any other statement made or purported to be made by it, or on its behalf, in connection with Oasmia and the new shares, or the rights offering, and nothing in this announcement is, or shall be relied upon as, a promise or representation in this respect, whether as to the past or future. Carnegie accordingly disclaims to the fullest extent permitted by law all and any responsibility and liability whether arising in tort, contract or otherwise which it might otherwise have in respect of this announcement or any such statement.

This press release contains forward-looking statements, which are statements related to future events. In this context, forward-looking statements often address Oasmia’s expected future business and financial performance, and often contain words such as "expect”, "anticipate”, "intend”, "plan”, "believe”, "seek”, or "will”. Forward-looking statements by their nature address matters that are, to different degrees, uncertain and can be influenced by many factors, including the behavior of financial markets, fluctuations in interest and exchange rates, commodity and equity prices and the value of financial assets; the impact of regulation and regulatory, investigative and legal actions; strategic actions; and numerous other matters of national, regional and global scale, including those of a political, economic, business and competitive nature. These factors may cause Oasmia’s actual future results to be materially different than those expressed in its forward-looking statements. Oasmia does not undertake to update its forward-looking statements.  

You are advised to read this announcement and, once available, the prospectus and the information incorporated by reference therein, in their entirety for a further discussion of the factors that could affect Oasmia’s future performance and the industries in which it operates. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements in this announcement may not occur.

         Anders Lundin, CFO
         Mobile: +46 702 09 63 00
         E-mail: anders.lundin@oasmia.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 60

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand

Updated Category News Views 69

A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 85

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 53

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 120

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 92

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 106

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 94

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 182

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 110

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading

Top 5 Most Recently Viewed Articles

MINISH Technology's Milestone: First U.S. Veneers Certification Success

Updated Category News Views 201

MINISH Technology Concludes First U.S. Veneers Course Health-tech company MINISH Technology Inc. has recently achieved a remarkable milestone by successfully completing its first MINISH Veneers course in the United States, certifying 22 dedicated dentists. This event highlights a significant step forward in the company’s commitment to advancing dental education and...

Continue Reading
Exciting Developments for Stellar V Capital Corp.'s Trading Options

Updated Category News Views 130

Stellar V Capital Corp. Announces Upcoming Trading Changes NEW YORK — Stellar V Capital Corp., a rising star in the acquisition space, has exciting news for its investors. Beginning March 24, 2025, holders of the units sold during the Company’s initial public offering will have the option to trade the Class A ordinary shares separately from the associated warrants....

Continue Reading
DelNorte’s Groundbreaking Data Tokenization Initiative Unveiled

Updated Category News Views 1405

Revolutionizing Public Data Management with DelNorte In an exciting move aimed at improving how public data is handled, DelNorte has partnered with a significant government body to initiate a cutting-edge data tokenization project. This initiative is centered around the introduction of the DTV Token, a vital component of DelNorte's innovative Terra Vision ecosystem,...

Continue Reading
Celebrating Success at the AMPLIFY A|E|C Conference

Updated Category News Views 67

WB Engineers+Consultants at the AMPLIFY A|E|C Conference Recently, WB Engineers+Consultants was proud to represent its ethos of innovation and excellence at the AMPLIFY A|E|C 2024 conference, a key event dedicated to the architecture, engineering, and construction (A/E/C) sectors. This distinguished conference was organized by the Society for Marketing Professional...

Continue Reading
Calix Faces Legal Fire Over Alleged Securities Missteps

Updated Category News Views 51

Calix Hits a Legal Snag: What's at Stake? In the gritty world of stock trading, nothing gets folks more riled up than talk of lawsuits—and here comes Calix, Inc. (NYSE: CALX) caught in a thorny one. Straight out of Los Angeles, the DJS Law Group beams a flare into the sky, reminding investors of a class action lawsuit tagged to violations of the Securities Exchange Act...

Continue Reading